^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    DCTY0801

    i
    Other names: DCTY0801, EGFRvIII CAR-T, DCTY-0801, DCTY 0801
    Associations

    News

    Trials
    Company:
    Beijing DCTY Biotech
    Drug class:
    EGFRvIII-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    over1year
    A Study to Evaluate the Safety, Tolerance and Initial Efficacy of EGFRvIII CAR-T on Glioblastoma (clinicaltrials.gov)
    P1, N=22, Not yet recruiting, Beijing Tsinghua Chang Gung Hospital | Trial completion date: Apr 2025 --> Jul 2025 | Initiation date: Apr 2023 --> Jul 2023 | Trial primary completion date: Apr 2025 --> Jul 2025
    Trial completion date • Trial initiation date • Trial primary completion date • IO biomarker
    |
    EGFRvIII expression
    |
    DCTY0801